EU pharma industry urges deregulation and faster approvals to rival US, China

At a Santander gathering, the pharmaceutical industry argues Europe's competitiveness is hampered by bureaucracy and slow approval timelines, calling for shorter deadlines to accelerate patient access. This reflects a broader industry push for regulatory reform amid competitive pressure from the US and China. The outcome is uncertain as it depends on EU policy response.